References

  • Berntorp E, Archey W, Auerswald G, Federici AB, Franchini M, Knaub S, et al. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate-P/Humate-P: history and clinical performance. Eur J Haematol. 2008;80(Suppl 70):3-35.
  • Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA, for the Humate-P Study Group. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003;9(6):688-695.
  • Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Clin N Am. 2007; 21:1-11.
  • Kleinert D, Orto C, Gioia K, Hannan M. Von Willebrand Disease: a nursing perspective. J Obstet Gynecol Neonatal Nurs. 1997;26:271-276. 5. National Hemophilia Foundation. What is von Willebrand disease? http://www.hemophilia.org/ NHFWeb/MainPgs/ MainNHF.aspx?menuid=182&contentid=47&rptname=bleeding. Accessed September 23, 2011.
  • Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate® ) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001:7;258–266.
  • Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM, for the Haemate P Surgical Study Group. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost. 2007;5(7):1420-1430.
  • Lillicrap D, Poon M-C, Walker I, Xie F, Schwartz BA, and members of the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002;87(2):224-230.
  • Mannucci PM. How I treat patients with von Willebrand disease. Blood. 2001;97(7):1915-1919.
  • Mason RG, Saba HI. Normal and abnormal hemostasis—an integrated view. Am J Pathol. 1978;92(3):775-812.
  • National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of von Willebrand Disease. Bethesda, MD: National Institutes of Health; 2007. NIH Publication No. 08-5832.
  • National Hemophilia Foundation. What is a bleeding disorder? http://www.hemophilia.org/NHFWeb/MainPgs/ MainNHF .aspx?menuid=26&contentid=5&rptname=bleedingAccessed September 23, 20011.
  • National Hemophilia Foundation. Glossary. http://www.hemophilia.org/NHFWeb/ MainPgs/MainNHF.aspx?menuid=39& contentid=28.
  • Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA; Humate-P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia. 2004;10(1):42-51.

Important Safety Information

Stimate® (desmopressin acetate) Nasal Spray, 1.5 mg/mL is a treatment used to stop some types of bleeding in people with mild hemophilia A or mild to moderate von Willebrand disease (VWD) Type 1. Stimate Nasal Spray should not be used in children under 11 months of age.

All patients using Stimate Nasal Spray are at risk of water intoxication, fluid overload and low sodium levels in the blood. Follow your healthcare provider’s instructions on limiting the amount of fluid you drink when using Stimate Nasal Spray, as too much fluid intake can lead to serious adverse reactions, including seizures, coma, and even death. Fluid restrictions are especially important for children and elderly patients, as they are at higher risk for these reactions.

See the patient information leaflet in the prescribing information for Stimate Nasal Spray for symptoms that could mean your blood sodium level is low—including headache, hallucinations, confusion, restlessness, weight gain and muscle spasms. Immediately report any of these symptoms to your physician or, if necessary, an emergency department. Also contact your doctor immediately if you have uncontrolled bleeding.

Before being prescribed Stimate Nasal Spray, make sure your doctor knows about all your medical conditions and about any medications you are taking. Use Stimate Nasal Spray exactly as your healthcare provider has instructed.

Side effects of Stimate Nasal Spray generally come from having too much water in the body. The most common include facial flushing, nasal congestion, runny nose, nose bleed, sore throat, cough, and upper respiratory infections. Tell your healthcare provider if you experience a side effect that does not go away.

Please see full prescribing information for Stimate Nasal Spray

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.